Printer Friendly

Ono Pharmaceutical Announces Establishment of Strategic Alliance Headquarters.

Tokyo, Japan, Feb 27, 2007 - (JCN Newswire) - Ono Pharmaceutical Co., Ltd. announced today that as of March 1, 2007 the Discovery Research Alliance of the Research Headquarters and the International Business of the Development Headquarters will be integrated in a constructive way into one unit to establish a Strategic Alliance Headquarters.

In order to achieve its goal of serving as an R&D-oriented, international pharmaceutical company (global speciality) specializing in defined areas of research based on unique idea of "compound oriented"* that is totally different from other companies in the industry, Ono has striven to discover original and innovative new drugs conforming to global standard in the company's four priority fields: prostaglandins, enzyme inhibitors, neuroscience, and intracellular signaling, where we can fully benefit from the technologies we have accumulated in the past, and now adding genomic drug discovery on top of these four areas.

Discovery Research Alliance, newly created in April 2005, is aggressively seeking and promoting alliances with bioventure companies and research institutions within and outside Japan in order to strengthen discovery research capability by gaining access to cutting-edge technologies and discovery seeds. This newly established section has already made remarkable achievements as launching collaborative drug discovery programs relating to inhibitors of kinase, one of the intracellular enzymes that is involved in various diseases, with two U.S. bioventure companies.

Further to that, Ono has made efforts to strengthen our development pipeline by acquiring in-licensing products aggressively. This time, International Business of Development Headquarters that has been in charge of inand out-licensing activities and Discovery Research Alliance of Research Headquarters that has pursued search and alliances of discovery seeds will be integrated in a constructive way into one unit as establishing Strategic Alliance Headquarters in order to further strengthen discovery research capability and expansion of development pipeline by promoting strategic alliances. Strategic Alliance Headquarters is anticipated to take an important role in improving overall research and development capability while closely coordinating with Research Headquarters and Development Headquarters.

Discovery Research Alliance

Discovery Research Alliance is aggressively seeking and promoting collaborative research and alliances with bioventure companies and research institutions such as universities mainly in the U.S. and Europe in order to strengthen discovery research capability and development pipeline by gaining access to discovery seeds and cutting-edge technologies.

The section is aiming at 10 new discovery alliances to be acquired from bioventure companies and new research alliances to be collaborated with 20 to 30 universities within and outside Japan during the next 5 years.

Business Development

The focus had been on in-licensing new drug candidates of later stages of development at Business Development, but in future the section will also direct its effort into acquiring early stage development compounds (preclinical and Phase I stage) in order to further expand our development pipeline.

The section is aiming at in-licensing 10 new compounds during the next 5 years.

Licensing and Business Research

Licensing and Business Research section will perform information search and collection for business alliances and promote contract negotiation by obtaining cross-sectional cooperation from other headquarters on demand.

* Compound oriented: It is an idea that development and commercialization compounds generated from inquisitive mind of scientists towards newly discovered vital phenomena and unique theories are pursued without identifying specific disease areas.

About Ono Pharmaceutical Co Ltd.

Ono Pharmaceutical Co Ltd.(TSE: 4528) Manufacturer and marketer of prescription pharmaceutical products, OTC drugs. Operations are carried out through the following sectors: Pharmaceuticals (Digestive agents, Circulatory & respiratory agents, Vitamins & metabolic agents, Diagnostics reagents); Services and Other operations (Printing, Publishing, Distribution, Insurance agnecy, Transportation). Pharmaceuticals accounted for 100% of fiscal 2001 revenues; services and other operations, nominal.

Source: Ono Pharmaceutical Co Ltd.

Contact:
Ono Pharmaceutical Co., Ltd.
Public Relations
Phone: +81-6-6263-5670
Fax: +81-6-6263-2950


Copyright [c] 2007 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K.
COPYRIGHT 2007 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCN Newswires
Date:Feb 28, 2007
Words:634
Previous Article:Toyota to Build Vehicle Plant in Mississippi, U.S.A.
Next Article:JETRO Monthly Survey, Japanese Business Sentiment in East Asia Continues Mixed in February.
Topics:


Related Articles
Ono Pharmaceutical Announces Changes in Investigational AIDS Drug Development Program.
Ono Pharmaceutical Announces Termination of Patient Enrollment for Phase III Clinical Trial of Investigational AIDS Drug.
Ono Pharmaceutical, Array BioPharma to Collaborate in Kinase-targeted Drug Discovery.
Ono Pharmaceutical, Dainippon Sumitomo Pharma to Enter into Joint Development and Marketing Agreement for Limaprost Alfadex, Oral PGE1 Derivative.
Eisai Establishes European Strategic Business Hub in the U.K.
Ono Pharmaceutical, Medarex to Collaborate in Research on Fully Human Antibody.
Ono Pharmaceutical, Banyu Pharmaceutical Jointly Confirm Hypoglycemic Effect of DPP4 Inhibitor Sitagliptin.
Banyu and Ono Begins Phase III Clinical Trials of a DPP-4 Inhibitor for Type 2 Diabetes Patients.
GIVE THIS PIECE A CHANCE.
Ono Licenses Cancer Anorexia/Cachexia Drug from Sapphire Therapeutics for Japan, Korea and Taiwan.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters